CORE PHARMACEUTICALS LIMITED

Active United Kingdom

Wholesale of pharmaceutical goods

9 employees website.com
Life sciences and medical technology Wholesale of pharmaceutical goods
C

CORE PHARMACEUTICALS LIMITED

Wholesale of pharmaceutical goods

Founded 4 Aug 2020 Active United Kingdom 9 employees website.com
Life sciences and medical technology Wholesale of pharmaceutical goods
Accounts Submitted 4 Jan 2026 Next due 31 Dec 2026 6 months remaining
Confirmation Submitted 6 May 2026 Next due 25 Apr 2027 10 months remaining
Net assets £-186K £120K 2024 year on year
Total assets £1M £944K 2024 year on year
Total Liabilities £1M £1M 2024 year on year
Charges None No charges registered

Contact & Details

Contact

Telephone

0800 000 0000

Website

www.example.com

Full company profile for CORE PHARMACEUTICALS LIMITED (12792227), an active life sciences and medical technology company based in United Kingdom. Incorporated 4 Aug 2020. Wholesale of pharmaceutical goods. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Apr → 31 Mar 2025
Type audit-exemption-subsidiary
Next accounts 31 Mar 2026
Due by 31 Dec 2026 6 months remaining

Net Assets, Total Assets & Total Liabilities (2021–2024)

Cash in Bank

£58.26k

Increased by £54.34k (+1385%)

Net Assets

-£186.02k

Decreased by £120.13k (-182%)

Total Liabilities

£1.27M

Increased by £1.06M (+517%)

Turnover

N/A

Employees

9

Increased by 7 (+350%)

Debt Ratio

117%

Decreased by 30 (-20%)

Financial History

Revenue, profit, EBITDA and key financial figures

2025
31 Mar Year End
2024
31 Jul Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

No fundraising or grants recorded

Investors (0)

No investor information available

Officers

Officers

1 active 1 resigned
Status
Abdullah, SuhaibDirectorBritishEngland516 Jun 2023Active

Shareholders

Shareholders (2)

Sharief Group Limited
100.0%
100
Khadija Sami
0.0%
0

Persons with Significant Control

Persons with Significant Control (2)

2 Active 1 Ceased

Khadija Sami

British

Active
Notified 4 Aug 2020
Residence England
DOB March 1982
Nature of Control
  • Ownership Of Shares 75 To 100 Percent,voting Rights 75 To 100 Percent,right To Appoint And Remove Directors

Sharief Group Limited

United Kingdom

Active
Notified 4 Aug 2024
Nature of Control
  • Ownership Of Shares 75 To 100 Percent

Mrs Khadija Sami

Ceased 4 Aug 2024

Ceased

Group Structure

Group Structure

SHARIEF GROUP LIMITED united kingdom
CORE PHARMACEUTICALS LIMITED Current Company

Charges

Charges

No charges registered

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
6 May 2026Confirmation StatementConfirmation statement made on 11 Apr 2026 with updates
6 May 2026Persons With Significant ControlCessation of Khadija Sami as a person with significant control on 4 Aug 2024
4 Jan 2026OtherNotice of agreement to exemption from audit of accounts for period ending 31/03/25
4 Jan 2026OtherAudit exemption statement of guarantee by parent company for period ending 31/03/25
4 Jan 2026AccountsAnnual accounts made up to 31 Mar 2025
6 May 2026 Confirmation Statement

Confirmation statement made on 11 Apr 2026 with updates

6 May 2026 Persons With Significant Control

Cessation of Khadija Sami as a person with significant control on 4 Aug 2024

4 Jan 2026 Other

Notice of agreement to exemption from audit of accounts for period ending 31/03/25

4 Jan 2026 Other

Audit exemption statement of guarantee by parent company for period ending 31/03/25

4 Jan 2026 Accounts

Annual accounts made up to 31 Mar 2025

Recent Activity

Latest Activity

Confirmation statement made on 11 Apr 2026 with updates

1 months ago on 6 May 2026

Cessation of Khadija Sami as a person with significant control on 4 Aug 2024

1 months ago on 6 May 2026

Notice of agreement to exemption from audit of accounts for period ending 31/03/25

5 months ago on 4 Jan 2026

Audit exemption statement of guarantee by parent company for period ending 31/03/25

5 months ago on 4 Jan 2026

Annual accounts made up to 31 Mar 2025

5 months ago on 4 Jan 2026